ÍÑÒÂÖ±²¥

The purpose of this study is to evaluate the effectiveness of Heart Rate Variability Biofeedback (HRVB) in improving heart health, reducing stress and improve sleep among cancer survivors. Approximately 45 patients will be enrolled into this study.

HRVB is a technique that uses slow breathing exercises to improve nervous system function, reduce stress, enhance relaxation, and support heart health. This study will guide subjects through paced breathing exercises while monitoring subjects' heart rate using a portable device.

In order to participate you must meet the following criteria:

• Are an adult 40–75 years of age.
• Are a male or female survivor diagnosed with breast, lung, endometrial or any type of head and neck cancer within 12 months of study entry.
• Have completed all cancer-related treatments, including chemotherapy, radiation, and surgery. Patients may still be receiving endocrine therapy.
• Are of any ethnic background. The study will have at least 50% African American/Hispanic representation.
• Are willing to attend two visits at Rush Cancer Center and complete daily heart rate variability (HRV) biofeedback sessions (20 minutes/day) for 12 weeks.

You will be excluded from the study if any of the following criteria apply to you:

• Are a current smoker.
• Have a history of substance use.
• Have untreated obstructive sleep apnea.
• Have a history of seizure disorders.
• Have a history of cardiac arrhythmia.
• Have use of serotonin and norepinephrine reuptake inhibitors (SNRIs).
• Have concurrent participation in other biofeedback interventions.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.